Income Taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Deferred Tax Assets and Liabilities

Significant components of Delek's deferred tax assets (liabilities) reported in the accompanying consolidated financial statements as of December 31, 2020 and 2019 were as follows (in millions):

	December 31,
	2020		2019
Non-Current Deferred Taxes:
Property, plant and equipment, and intangibles	$	(261.0)	$	(306.3)
Right-of-use asset	(35.1)		(40.7)
Partnership and equity investments	(133.3)		(15.5)
Deferred revenues	(4.8)		(5.3)
Total deferred tax liabilities	(434.2)		(367.8)
Compensation and employee benefits	13.6		14.5
Net operating loss carryforwards	136.4		52.4
Tax credit carryforwards	17.0		—
Lease obligation	35.2		40.7
Reserves and accruals	33.4		48.3
Other	4.1		9.8
Total deferred tax assets	239.7		165.7
Valuation allowance	(55.0)		(65.8)
Total net deferred tax liabilities (1)	$	(249.5)	$	(267.9)

(1)     Total net deferred tax liabilities includes $6.0 million of state deferred tax assets recorded in other non-current assets in our consolidated balance sheet.

Schedule of Effective Income Tax Rate Reconciliation

The difference between the actual income tax expense and the tax expense computed by applying the statutory federal income tax rate to income from continuing operations was attributable to the following (in millions):

	Year Ended December 31,
	2020		2019		2018
Provision for federal income taxes at statutory rate	$	(160.3)	$	84.6	$	102.0
State income tax (benefit) expense, net of federal tax provision	(11.3)		6.3		3.4
Income tax benefit attributable to non-controlling interest	(7.9)		(5.4)		(7.3)
Tax credits and incentives (1)	(9.6)		(23.2)		(8.3)
Changes in valuation allowance	(10.8)		7.3		7.7
Impact of Tax Reform Act	—		—		(0.6)
Impact of CARES Act NOL carryback	(16.8)		—		—
Goodwill impairment	21.4		—		5.3
Other items	2.6		2.1		(0.3)
Income tax (benefit) expense	$	(192.7)	$	71.7	$	101.9

(1)     Tax credits and incentives include work opportunity and research and development credits, as well as incentives for the Company’s biodiesel blending operations.

Schedule of Components of Income Tax Expense (Benefit)

Income tax (benefit) expense from continuing operations was as follows (in millions):

	Year Ended December 31,
	2020		2019		2018
Current	$	(160.6)	$	7.1	$	128.7
Deferred	(32.1)		64.6		(26.8)
	$	(192.7)	$	71.7	$	101.9

Schedule of Unrecognized Tax Benefits Roll Forward

Increases and decreases to the beginning balance of unrecognized tax benefits, which includes interest and penalties were as follows (in millions):

	Year Ended December 31,
	2020		2019		2018
Balance at the beginning of the year	$	12.1	$	19.2	$	6.1
Additions based on tax positions related to current year	1.9		0.4		11.2
Additions for tax positions related to prior years and acquisitions	2.4		6.4		3.4
Reductions for tax positions related to prior years	(0.8)		(13.0)		(0.9)
Reductions for tax positions related to lapse of applicable statute of limitations	(0.2)		—		—
Settlements with taxing authorities	(5.8)		(0.9)		(0.6)
Balance at the end of the year	$	9.6	$	12.1	$	19.2